Strategy question
Abridge can solve a clinical documentation workload with four options: a frontier API, an open-source model, a prompted/routed workflow, or an in-house trained model. Build a decision framework for choosing among them. Which criteria would be hard gates versus tradeoff variables, and how would you weigh durable strategic advantage against near-term speed, quality, latency, cost, safety, and controllability?
- Abridge
- Strategy
- Hard
Practice this question out loud. An AI interviewer asks it, follows up like a real interviewer would, and scores your answer. Type or speak.
Start a mock interview on this question · Mock interview from a job description
What this question tests
Tests building a decision framework across four model-sourcing options for a high-stakes clinical workload, separating hard gates from tradeoff variables.
How to approach it
- Set hard gates first: clinical safety and accuracy must clear a minimum bar on a held-out eval set, and data handling must meet HIPAA and enterprise security requirements, regardless of option chosen.
- List tradeoff variables: speed to deploy, ongoing cost, latency, controllability over model behavior, and durable strategic advantage from owning the model.
- Score each option, frontier API, open-source, prompted or routed workflow, in-house trained model, against the tradeoff variables, not the hard gates, since those are pass or fail.
- Weigh near-term needs, likely favoring a frontier API or routed workflow for speed and quality today, against long-term differentiation, which favors post-training or in-house investment over time.
- Recommend a staged path: start with a frontier API or routed workflow to hit the market now, while incrementally investing in post-training or in-house capability as proprietary clinical data accumulates.
- Set a revisit trigger, for example once enough clinician-edit data exists to meaningfully improve an in-house model, to reassess the decision.
What a strong answer includes
- Separates hard gates, safety and compliance, from tradeoff variables, cost and speed, so the framework doesn't conflate must-haves with nice-to-haves.
- Recommends a staged approach, frontier API now with in-house investment growing over time, rather than a single permanent choice.
- Names durable strategic advantage explicitly as owning proprietary clinical data and model behavior, which a pure API dependency can't provide.
- Sets a concrete revisit trigger tied to data accumulation, not just a calendar date.
Common mistakes
- Treating cost or speed as a hard gate when clinical safety should be the only non-negotiable filter.
- Picking one option permanently without a plan to revisit as data and capabilities mature.
- Ignoring controllability and safety monitoring needs specific to a clinical, regulated use case.
Likely follow-up questions
- What would move you from a frontier API to in-house sooner than planned?
- How would you monitor an open-source or routed option's safety once in production?
More strategy questions
- Abridge must decide whether to build, license, or partner for new evidence sources such as guidelines, journals, or point-of-care references. Walk through the decision framework you would use for one new source, including quality, coverage, workflow fit, differentiation, economics, and the threshold that must be met before you would allow that source into a high-stakes clinical product.Abridge · Strategy · Hard
- For a core workflow in Epic, how would you decide whether to build the experience embedded inside the EHR, in a standalone Abridge surface, or as a hybrid? Compare the options on clinician adoption, workflow speed, integration constraints, release velocity, data access, and defensibility, and explain how your choice would shape the roadmap.Abridge · Strategy · Hard
- You need to introduce eval gates from prototype to GA to steady-state monitoring across teams you do not manage directly. How would you set hard vs. advisory gates, assign ownership for non-negotiable floors like critical-error rates, and drive adoption across pods without slowing shipping velocity?Abridge · Strategy · Hard
- A CMIO is pushing for a bespoke feature that would materially help their deployment, but you believe it will not generalize to Abridge’s core product. What decision framework would you use to choose between building it in the forward-deployed engagement, declining it, or routing it to the core roadmap, and how would you communicate that decision without damaging the relationship?Abridge · Strategy · Hard
- You are two weeks into a six-week forward-deployed engagement when three things happen at once: the partner asks for additional scope, engineering finds an integration blocker, and executives want a firm go-live date. How would you re-scope the work, protect pod focus and pace, make the right trade-offs, and keep hospital leadership aligned on an outcome that is still worth shipping?Abridge · Strategy · Hard
- Google Keep is a free product to save, share notes etc. How would you make it a subscription product & monetize it?Google · Strategy · Hard
More questions from Abridge
Learn the skill behind it
Chapters of the AI PM course that teach what this question tests.
- Chapter 4: Discovery and strategy for AI products
- Chapter 9: Prove it paid off: outcomes, economics, and pricing
- Chapter 14: Get the job: the AI PM interview loop